Latest From Orexo AB
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.
US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist
The CEO of Swedish addiction and pain specialist Orexo tells Scrip its top drug Zubsolv will grow strongly in coming years to address the opioid crisis in the US, and that revenues will be further boosted by novel pipeline therapies likely to be commercialized in coming years.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- Orexo Pharmaceuticals AB
- Western Europe
- Parent & Subsidiaries
- Orexo AB
- Senior Management
Nikolaj Sorensen, CEO
Michael Sumner, PhD, CMO
Jesper Lind, COO
- Contact Info
Phone: (46) 18 780 88 00
P.O. Box 303 Uppsala, SE 751 05
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.